Advertisement

International Journal of Hematology

, Volume 106, Issue 6, pp 820–831 | Cite as

Risk factors in patients undergoing haploidentical hematopoietic stem cell transplantation for high-risk childhood acute leukemia

  • Dong-mei Han
  • Xiao-li Zheng
  • Li Ding
  • Hong-min Yan
  • Zhi-dong Wang
  • Mei Xue
  • Ling Zhu
  • Jing Liu
  • Heng-xiang Wang
Original Article
  • 338 Downloads

Abstract

In the present study, we sought to analyze the risk factors following haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in children with high-risk acute leukemia. We retrospectively reviewed data from 73 children with high-risk leukemia. Univariate and multivariate analyses were performed to evaluate relationships between variables and patient outcomes. The mean time for neutrophil engraftment was significantly shorter in children given a graft with a higher number of nucleated cells (>10.13 × 108/kg vs ≤10.13 × 108/kg: 13.79 ± 2.73 vs 17.71 ± 3.90 days, P < 0.001) and in younger children (≤10 years vs >10 years: 14.21 ± 3.12 vs 17.71 ± 3.90 days, P < 0.001). Time to platelet engraftment was clearly shorter in children given a graft with higher number of nucleated cells (>10.13 × 108/kg vs ≤10.13 × 108/kg: 12.12 ± 8.62 vs 32.1 ± 24.83 days, P < 0.028). Overall survival was 64.6 ± 9.1%, 41.1 ± 10.1%, and 81.6 ± 9.6%, respectively, in children with HR-ALL in CR1, ALL in CR2–4, and AML (P = 0.012). The number of total nucleated cells was significantly associated with transplant-related mortality (TRM). We suggest that outcomes of haplo-HSCT may be improved by increased infusion of nucleated cells.

Keywords

High-risk childhood acute leukemia Haploidentical hematopoietic stem cell transplantation Risk analysis 

References

  1. 1.
    Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78.CrossRefPubMedGoogle Scholar
  2. 2.
    Conter V, Valsecchi MG, Parasole R, Putti MC, Locatelli F, Barisone E, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood. 2014;123:1470–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Marshall GM, Dalla PL, Sutton R, Ng A, de GrootKruseman HA, Vh VDV, et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia. 2013;27:1497–503.CrossRefPubMedGoogle Scholar
  4. 4.
    Pulsipher MA, Peters C, Pui CH. High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2011;17:137–48.CrossRefGoogle Scholar
  5. 5.
    Balduzzi A, Valsecchi MG, Uderzo C, Lorenzo PD, Klingebiel T, Peters C, et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet. 2005;366:635–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006;24:5742–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Peters C, Schrauder A, Schrappe M, Stackelberg AV, Stary J, Yaniv I, et al. Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM|[sol]|IBFM|[sol]|EBMT concepts. Bone Marrow Transplant. 2005;35(Suppl 1):S9–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Lang P, Handgretinger R, Niethammer D, Schlegel PG, Schumm M, Greil J, et al. Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood. 2003;101:1630–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood. 2010;115:3437–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high risk acute leukaemia with T-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem cell transplantation. Transplantation. 2009;88:1019–24.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Huang XJ. Current status of haploidentical stem cell transplantation for leukemia. J Hematol Oncol. 2008;1:1–9.CrossRefGoogle Scholar
  13. 13.
    Kang Y, Chao NJ, Aversa F. Unmanipulated or CD34 selected haplotype mismatched transplants. Curr Opin Hematol. 2008;15:561–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, et al. Conditioning including antithymocyte globulin followed by un-manipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes to HLA-identical sibling transplantation. Blood. 2006;107:3065–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Xiaojun H, Lanping X, Kaiyan L, Daihong L, Huan C, Wei H, et al. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med. 2008;40:444–55.CrossRefGoogle Scholar
  16. 16.
    Huang XJ, Liu DH, Liu KY, Xu LP. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2009;15:257–65.CrossRefGoogle Scholar
  17. 17.
    Jaffe ES, Harris ES, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. WHO Classification of Tumours. Lyon: IARC Press; 2001.Google Scholar
  18. 18.
    Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant. 2008;41:473–81.CrossRefPubMedGoogle Scholar
  19. 19.
    Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611–8.PubMedGoogle Scholar
  20. 20.
    Page KM, Zhang L, Mendizabal A, Wease S, Carter S, Gentry T, et al. Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant. 2011;17:1362–74.CrossRefPubMedGoogle Scholar
  21. 21.
    Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344:1815–22.CrossRefPubMedGoogle Scholar
  22. 22.
    Chang YJ, Xu LP, Liu DH, Liu KY. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2009;15:632–8.CrossRefGoogle Scholar
  23. 23.
    Yu W, Liu DH, Liu Kai-Yan, Lan-Ping Xu, Zhang Xiao-Hui, Wei HM, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. Cancer. 2013;119:978–85.CrossRefGoogle Scholar
  24. 24.
    Kim HJ, Park SJ, Im HW, Dong WK, Min WS, Kim HK, et al. The association of HLA antigen and GVHD in allogeneic hemopoietic stem cell transplantation with histocompatible sibling donor: a single-center experience in Korea. Int J Hematol. 2002;76:267–71.CrossRefPubMedGoogle Scholar
  25. 25.
    Huo MR, Xu LP, Li D, Liu DH, Liu KY, Chen H, et al. The effect of HLA disparity on clinical outcome after HLA-haploidentical blood and marrow transplantation. Clin Transplant. 2012;26:284–91.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Dong-mei Han
    • 1
  • Xiao-li Zheng
    • 1
  • Li Ding
    • 1
  • Hong-min Yan
    • 1
  • Zhi-dong Wang
    • 1
  • Mei Xue
    • 1
  • Ling Zhu
    • 1
  • Jing Liu
    • 1
  • Heng-xiang Wang
    • 1
  1. 1.Department of HematologyGeneral Hospital of the Air ForceBeijingChina

Personalised recommendations